Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
1.150
0.00 (0.00%)
At close: Dec 20, 2024, 2:54 PM
1.210
+0.060 (5.22%)
After-hours: Dec 20, 2024, 7:44 PM EST
Theriva Biologics Employees
Theriva Biologics had 22 employees as of December 31, 2023. The number of employees increased by 1 or 4.76% compared to the previous year.
Employees
22
Change (1Y)
1
Growth (1Y)
4.76%
Revenue / Employee
n/a
Profits / Employee
-$1,213,227
Market Cap
3.17M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| China Pharma Holdings | 231 |
| Aditxt | 47 |
| Windtree Therapeutics | 20 |
| Sonoma Pharmaceuticals | 10 |
| Pasithea Therapeutics | 8 |
| NLS Pharmaceutics AG | 7 |
| Enveric Biosciences | 7 |
TOVX News
- 16 days ago - Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - GlobeNewsWire
- 3 months ago - Theriva Biologics Announces Pricing of $2.5 Million Public Offering - GlobeNewsWire
- 3 months ago - Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 3 months ago - Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program - GlobeNewsWire
- 4 months ago - Theriva Biologics Announces Reverse Stock Split - GlobeNewsWire
- 5 months ago - Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma - GlobeNewsWire
- 7 months ago - Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire